Fat Grafting in Mobile Alabama
As we grow older our face become more and more affected by the sun, gravity and use of expression muscles (chewing, smiling, etc). Deep tissues loose the ability to maintain a young look and expression marks appear on our faces. Fat grafting can help you fill the defects and regain younger appearance. It can be used to fill expression folds, sunken checks, scars and lips. This procedure is not sufficient to treat deep defects like multiple grooves around the mouse of heavy smokers. It can be done as isolated treatment or as a combination with laser, facelift and botox.
During the procedure the surgeon performs a liposuction from various body parts like thighs, tummy and buttocks and then injects the fat into selected areas needs to be filled. After disinfection of the donor and recipient areas, they are being sedated using local anesthetics. Sedative drugs also can be used, if so you may need an escort to avoid driving under their influence. For liposuction the surgeon uses wide needle or canola. After a short treatment the fat is injected to the desired site. The recipient area is usually bandaged. In order to fill sunken chicks often over filling is required because of absorption process of some of the fat injected. This can make your face appear over swollen immediately after the operation.
If the area treated is extensive it is advisable to restrain from activities after the treatment. Although most of the patients can go back to their daily activities right away. There might be redness, swelling and small hemorrhages around both the donor and the recipient sites. The severity of those symptoms usually depends on the magnitude of the procedure. It is advisable to avoid sun exposure until the above disappear (after approximately 48 hours). There is no limitation to use make-up. The swelling can last for weeks especially if the area is large. Every operation has its ricks. The fat being taken from the patient's body doesn't cause allergic responses. There is a small chance of infection.
You must remember that the effect of the injection is only temporary. Due to their biological nature the injected materials disassemble by the body. The duration of the effect depends on genetics, age, skin quality, life style and the area being filled. There are selected cases where the results lasted for a year, but in most cases half of the effect disappears after 3-6 month.
More Mobile info...
Mobile By air
Mobile Regional Airport (MOB); 8400 Airport Blvd; [1] is the main airport airport servicing Mobile.
Mobile Downtown Airport (Brookley Complex); 1891 9th Avenue; Phone: (251) 438-7334;
Mobile Do
Ladd-Peebles Stadium, 1621 Virginia Street; [6]; This 40,000 seat stadium hosts college football games such as the GMAC Bowl in mid-December and the Senior Bowl in late-January.
Mobile BayBears, 755 Bolling Bros. Blvd; [7]; This baseball team is an AA Affiliate of the Arizona Diamondbacks. Their ballpark, Hank Aaron Stadium, is named for the baseball great who is from Mobile.
Mobile Greyhound Park, Old Pascagoula Rd. Theodore, AL 36582; [8]; Weekly Greyhound dog racing. Free admission, $2 valet. Dress code.
Gulf Coast Exploreum Science Center, 65 Government St.; [9]; Regional science center with exibits for all ages. Includes the only Domed IMAX Theater on the Gulf Coast.
Plastic Surgery News...
- BioSpace has reported briefly on Phase III data for retigabine, a first-in-class neuronal potassium channel opener which is in development as an adjunct in the treatment of adult epilepsy patients with refractory partial-onset seizures.
The double-blind trial – RESTORE 1 (Retigabine Efficacy and Safety Trials for Partial Onset Epilepsy) – randomised 306 adults who were experiencing refractory partial-onset seizures despite receiving stable doses of up to three anti-epileptics to additional treatment with retigabine (400mg TDS; n=151) or placebo (n=150). Study duration was 32 weeks including 8 weeks baseline phase, 6 weeks titration phase, 12 weeks maintenance phase and 6 weeks transition phase. Only brief details of the study are included in the BioSpace abstract which prevents a full evaluation of the findings; however the following results were reported:
• The median reduction in 28-day total partial seizure frequency was 44.3% in the retigabine group and 17.5% in the placebo group (p<0.0001)
• The median reduction in 28-day total partial seizure frequency during the maintenance phase was 54.5% versus 18.9%, respectively (p<0.0001)
• The responder rate (at least a 50% reduction in 28-day total partial seizure frequency) was 45.0% versus 18.0%, respectively (p<0.0001)
• The responder rate during the maintenance phase was 55.5% versus 22.6%, respectively (p<0.0001)
Results from RESTORE 2, the second pivotal Phase III clinical trial studying lower doses of retigabine, are expected during the second quarter of 2008. The company anticipate filing a Marketing Authorization Application (MAA) to the EMEA before the end of the year.
- FDA cannot meet requirements for inspections of medical device manufacturing facilities in the U.S. and abroad, according to a Government Accountability Office report scheduled for release on Tuesday at a hearing of the House Energy and Commerce Oversight and Investigations Subcommittee, the Wall Street Journal reports (Wilde Mathews, Wall Street Journal, 1/29).